We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Imatinib for Pain in Sickle Cell Anemia (IMPACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03997903
Recruitment Status : Recruiting
First Posted : June 25, 2019
Last Update Posted : July 29, 2022
Purdue University
Children's Hospital Medical Center, Cincinnati
Information provided by (Responsible Party):
Seethal Jacob, MD, MS, Indiana University

Brief Summary:
In this protocol, the investigators propose to evaluate the biochemical effects of imatinib on sickle red blood cells (RBCs). Patients will be administered imatinib mesylate orally following the guidelines previously established for use of imatinib in other disorders. The biochemical effects of imatinib on sickle RBCs will be examined, including changes in their levels of band 3 tyrosine phosphorylation and the abundances of RBC-derived microparticles in their blood. In addition, the patients will be monitored for symptoms of sickle cell disease (SCD). The investigators expect band 3 tyrosine phosphorylation to decrease dramatically in patients treated with imatinib. The investigators also anticipate a reduction in the numbers of RBC-derived microparticles in circulation (quantitated by assaying the number of glycophorin A positive microparticles in peripheral blood samples by flow cytometry. Most importantly, the investigators expect to see a reduction in the frequency of vaso-occlusive crises, and possibly acute chest syndrome and utilization of opioids. The study duration is planned as 6 months in order to provide adequate time for potential change in the primary endpoints (e.g. percent irreversibly sickled cells).

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: Imatinib Mesylate Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: IMatinib for PAin in Chronic Treatment of Sickle Cell Anemia (IMPACT SCA): A Pilot Study of Imatinib in Patients With Sickle Cell Anemia and Recurrent Vaso-occlusive Pain
Actual Study Start Date : February 26, 2020
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : September 2023

Arm Intervention/treatment
Experimental: Imatinib Intervention Drug: Imatinib Mesylate

The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.

Patients will receive Imatinib orally once daily for 6 months.

Primary Outcome Measures :
  1. Changes in Biochemical Effects - Band 3 Phosphorylation [ Time Frame: change from baseline Band 3 Phosphorylation at 7 months ]
    Percent change in Band 3 Phosphorylation tested in red blood cells

  2. Changes in Biochemical Effects - Microparticle Release [ Time Frame: change from baseline micro particle release at 7 months ]
    Percent change in Microparticle Release tested in red blood cells

  3. Change in Functional RBC analysis [ Time Frame: change from baseline functional RBC at 7 months ]
    Percent Irreversibly Sickled Cells by ektacytometry and Percent altered susceptibility to sickling by OxygenScan

Secondary Outcome Measures :
  1. Vaso-occlusive Crisis (VOC) [ Time Frame: monthly over 7 months ]
    Defined as an acute episode of pain lasting greater than 24 hours, with no medically determined cause other than a vaso-occlusive event that resulted in treatment with oral or parenteral opiate agents and/or parenteral nonsteroidal anti-inflammatory agents. Measured by pain scale (1-10) or Wong-Baker Faces scale based on age:

  2. Acute Chest Syndrome (ACS) [ Time Frame: monthly over 7 months ]
    Defined as respiratory distress (hypoxia, shortness of breath, chest pain, tachypnea) with evidence of an infiltrate on chest x-ray Measured with clinical evaluation.

  3. Opioid Use [ Time Frame: monthly over 7 months ]
    Defined as both oral and parenteral opioid use Oral use will be documented in pain diary by patient/guardian and reviewed at each visit.

  4. Hospitalizations [ Time Frame: monthly over 7 months ]
    Defined as an emergency room or clinic visit resulting in an inpatient admission or observation for a sickle cell-related event (e.g. vaso-occlusive pain, acute chest syndrome, etc).

  5. Assessment toxicities of imatinib in patients with sickle cell anemia (SCA) [ Time Frame: monthly over 7 months ]
    Clinical evaluation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 25 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age: patients must be ≥18 years of age and ≤25 years of age at the time of study entry.
  2. Diagnosis: Patients must have documented diagnosis of sickle cell disease (Hemoglobin SS Disease or S-Beta 0 Thalassemia) by either high pressure liquid chromatography (HPLC) or Hemoglobin Electrophoresis
  3. Disease status: Patients must have at least 2 documented episodes of vaso-occlusive pain in the prior year as defined by an acute episode of pain lasting greater than 24 hours, with no medically determined cause other than a vaso-occlusive event that resulted in treatment with oral or parenteral opiates or with a parenteral nonsteroidal anti-inflammatory drug.
  4. Performance Level: Karnofsky ≥80 for patients >10 years of age and Lansky ≥80 for patients ≤10 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  5. Organ function requirements:

    a. Adequate bone marrow function defined as i. Peripheral absolute neutrophil count (ANC) ≥1000/µL ii. Platelet count ≥100,000/ µL (transfusion independent) b. Adequate renal function defined as i. Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥70 mL/min/1.73 m2 or ii. A serum creatinine based on age/gender c. Adequate Liver Function Defined As: i. Total bilirubin (sum of conjugated + unconjugated) ≤1.5 times upper limit of normal (ULN) for age, and ii. serum glutamate pyruvate transaminase (SGPT or ALT) <2.5 upper limit of normal. For the purpose of this study, the ULN for SGPT is 45 U/L iii. Serum albumin ≥2 g/dL d. Adequate cardiac function defined as: i. Shortening fraction or ejection fraction greater than the institutional norm, and ii. Corrected QT interval ≤450 msec

  6. Informed Consent: All patients and/or their parents or legal guardians must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.

Exclusion Criteria:

  1. Chronic transfusion protocol.

    a. Patients currently on a chronic transfusion protocol are not eligible

  2. Hydroxyurea Intolerance

    a. Patients who are ineligible for hydroxyurea due to persistent marrow suppression (e.g. thrombocytopenia, neutropenia)

  3. Pregnancy or Breast-Feeding

    a. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.

  4. Concomitant Medications

    1. Investigational Drugs: Patients who are currently receiving another investigational drug.
    2. Anti-cancer agents: Patients who are currently receiving other anti-cancer agents.
    3. The following CYP3A4 inducers are prohibited 14 days before the start of imatinib and during the study with imatinib: rifampin, rifabutin, carbamazepine, Phenobarbital, phenytoin, St. John's wort, efavirenz, and tipranavir.
    4. The following CYP3A4 inhibitors are prohibited 7 days before the start of imatinib and during the study with imatinib: azole antifungals (itraconazole, ketoconazole); clarithromycin, erythromycin, diltiazem, verapamil, HIV protease inhibitors (indinavir, saquinavir, ritonavir, atazanavir, nelfainavir); delavirdine.
  5. Patients who have an uncontrolled infection.
  6. Prior use of Imatinib: Patients who have previously received imatinib are not eligible for study.
  7. Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
  8. Patient is < 5 years free of a malignancy. Existence of any other malignant disease is not allowed.
  9. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study).
  10. Patients with a history of QT prolongation, need for concomitant use of anti-arrhythmics or other agents known to prolong QT interval, or electrolyte derangement that cannot be corrected to within normal limits prior to initiation of study drug.
  11. Patients with a family history of sudden cardiac death.
  12. Patient has a severe and/or uncontrolled medical disease other than sickle cell disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
  13. Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
  14. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
  15. Patient had a major surgery within 2 weeks prior to study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03997903

Layout table for location contacts
Contact: Seethal Jacob, MD 317-944-8784 seejacob@iu.edu

Layout table for location information
United States, Indiana
Riley Hospital for Children at IU Health Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Anne Bubnick    317-948-0101    abubnick@iu.edu   
Principal Investigator: Seethal Jacob, MD         
United States, Ohio
Cincinnati Children's Hospital Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Charles Quinn, MD         
Sponsors and Collaborators
Indiana University
Purdue University
Children's Hospital Medical Center, Cincinnati
Layout table for additonal information
Responsible Party: Seethal Jacob, MD, MS, Assistant Professor of Pediatrics, Indiana University
ClinicalTrials.gov Identifier: NCT03997903    
Other Study ID Numbers: IMPACT SCA
First Posted: June 25, 2019    Key Record Dates
Last Update Posted: July 29, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Genetic Diseases, Inborn
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action